Roche’s next immuno-oncology combo is a big bet on Tigit

Roche’s next immuno-oncology combo is a big bet on Tigit

Source: 
EP Vantage
snippet: 

Almost in stealth mode the Swiss firm moves to begin a huge pivotal program rivalling that of the IDO and IL-2 mechanisms.